Business Context and Reporting Period
Pulmatrix, Inc. (PULM) filed a Form 8-K on April 9, 2020, reporting the entry into a Material Definitive Agreement. The Company, incorporated in Delaware, operates in the pharmaceutical sector with a focus on aerosol salt solutions for respiratory disease.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a new commercial agreement.
Material Changes and Agreement Terms
On April 9, 2020, Pulmatrix entered into a Collaboration and License Agreement with Sensory Cloud, Inc. Key terms include:
- Licensed Assets: Exclusive, worldwide, royalty-bearing license to PUR 003 and PUR 006 (NasoCalm) and related patents for over-the-counter (OTC) products targeting upper and lower respiratory diseases.
- Exclusions: The license excludes prescription products.
- Emergency Product: The agreement anticipates an emergency response product to reduce pathogenic risk and transmissibility of contagions, including COVID-19.
- Termination Rights: Pulmatrix may terminate if Sensory Cloud fails to meet specific regulatory and funding milestones for the Emergency Product within six months of the agreement date.
- Right of First Refusal: Sensory Cloud holds an exclusive right of first refusal for new OTC products developed by Pulmatrix in the field.
Financial Obligations and Milestones
The agreement establishes the following financial structure for Pulmatrix:
- Royalties:
- 7% of net sales in calendar year 2020.
- 14% of net sales in calendar year 2021.
- 17% of net sales in calendar year 2022 and thereafter.
- Milestone Payment: A one-time payment of $1,000,000 upon achievement of aggregate net sales of $20,000,000 for all Licensed Products.
- License Status: Upon expiration of patent claims and cessation of royalty payments, licenses become fully-paid up, royalty-free, perpetual, irrevocable, and non-exclusive.
Investor Verification Checklist
- Verify Sensory Cloud's progress toward the six-month regulatory and funding milestones for the Emergency Product to assess termination risk.
- Monitor the commercialization timeline for the OTC Licensed Products to evaluate the likelihood of royalty generation.
- Review the redacted portions of Exhibit 10.1 (Collaboration and License Agreement) if available through SEC supplemental requests to understand omitted competitive details.
- Confirm the specific definition of "net sales" within the full agreement to understand royalty calculation bases.